Chronic Administration of a Norepinephrine Antagonist Prevents and Partially Reverses Escalation of Cocaine Self-administration
Overview
Authors
Affiliations
Anxiety is a critical component of the development and maintenance of drug addiction; however, anti-anxiety medications such as benzodiazepines and beta-blockers (β-adrenergic receptor antagonists) are not used for the treatment of substance use disorder, except for the management of acute withdrawal syndrome. Preclinical studies have shown that beta-blockers may reduce stress-induced relapse; however, the effect of beta blockers on the escalation and maintenance of drug intake has not been tested. To address this issue, we chronically administered the β-adrenergic receptor antagonist propranolol during the escalation or maintenance of cocaine intake in a model of extended access (6 h) to cocaine self-administration (0.5 mg/kg). The behavioural specificity of propranolol was tested using a non-drug reward (saccharin). Daily administration of propranolol (15 mg/kg) prevented the development of escalation of cocaine self-administration and partially reversed self-administration after the establishment of escalation of intake. Moreover, propranolol dose-dependently decreased the motivation for cocaine tested under a progressive ratio schedule of reinforcement during the development of escalation and after maintenance. Finally, propranolol administration had no effect on the escalation and maintenance of saccharin self-administration. These results demonstrate that chronic treatment with propranolol provides therapeutic efficacy in reducing cocaine self-administration during the development and after the establishment of escalation of cocaine self-administration in an animal model relevant to cocaine use disorder. These results suggest that beta blockers should be further investigated as a target for medication development for the treatment of cocaine use disorder.
Pharmacological Treatments for Methamphetamine Use Disorder: Current Status and Future Targets.
Yates J Subst Abuse Rehabil. 2024; 15:125-161.
PMID: 39228432 PMC: 11370775. DOI: 10.2147/SAR.S431273.
Callan L, Caroland-Williams A, Lee G, Belflower J, Belflower J, Modi U Heliyon. 2024; 10(13):e32146.
PMID: 39027623 PMC: 11255514. DOI: 10.1016/j.heliyon.2024.e32146.
Sergio T, Jane Smith R, Wean S, Engleman E, Hopf F Sci Rep. 2024; 14(1):14029.
PMID: 38890353 PMC: 11189554. DOI: 10.1038/s41598-024-64565-9.
Sergio T, Jane Smith R, Wean S, Engleman E, Hopf F Res Sq. 2024; .
PMID: 38853968 PMC: 11160926. DOI: 10.21203/rs.3.rs-4402198/v1.
Lark A, Nass S, Hahn Y, Gao B, Milne G, Knapp P J Neurochem. 2024; 168(3):185-204.
PMID: 38308495 PMC: 10922901. DOI: 10.1111/jnc.16057.